Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Supaglutide

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)

Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 2/3 · Completed · Enrollment 620

NCT04998032

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
supaglutide RP3D dose+metforminn/rn/rn/rn/r
placebo+metforminn/rn/rn/rn/r

Not shown

  • supaglutide RP3D dose+metformin: endpoint not reported
  • placebo+metformin: endpoint not reported